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ABSTRACT
Cytokine and Nenrotransmitter Regulation of Glial 
Cell Production of IL-6; Indications for 
Neurodegerative Disorders
by
Scott Horrell
Dr. Bryan L. Spangelo, Examination Committee Chair 
Associate Professor 
University of Nevada, Las Vegas
There are two basic types of cells in the human brain: glial cells and neurons.
Neurons are responsible for the relay of information within the brain and between the 
brain and other organs. Glial cells represent two cell groups microglia (macrophages) 
and macroglia (astrocytes and oligodendrocytes). Activated microglia are the main 
generators of IL-1. Activated immunoreactive IL-1 microglia are increased sixfold in the 
central nervous system (CNS) of Alzheimer disease (AD) patients compared to age- 
matched controls and are associated with neuritic plaques. There is increasing evidence 
that plaque-associated activated glia and cytokines are important factors in the 
development and progression of the neuropathological hallmarks of AD.
Cytokines are mediators of the immune response and have the ability to aSect 
neuroendocrine function and hormone secretion. The cytokines interleukin-1 (IL-1) and 
interleukin-6 (IL-6) are produced during an immune reaction and cause inflammation and 
swelling of the surrounding tissue. AD is a neurodegenerative disorder characterized by
111
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well-defined neuropathologic entities. Both IL-1 and IL-6 are present in senile plaques 
and may cause a self-propagating inflammatory process that contributes to the disease 
processes of AD.
Somatostatin (SRIF) is a small, inhibitory neuropeptide present throughout the CNS. 
There are two types of SRIF found in mammals, SRIF-14 and 28. SRIF contributes to 
the maintenance of neuronal health in the adult and aging brain. AD causes the 
degeneration of somatostatin-containing neurons and an overall decrease of SRIF in the
CNS. This decrease of SRIF correlates with the distribution of senile plaques, 
neurofibrillary tangles and the cognitive degeneration of the patient. Because SRIF is an 
inhibitory neuropeptide we sought to determine the effects of SRIF on the production of 
IL-6 in rat C6 glial tumor cells. The release of IL-6 in the C6 cell conditioned media was 
quantified using the IL-6 dependent 7TD1 hybridoma bioassay.
Both SRIF-14 and 28 significantly reduced the IL-1 stimulation of IL-6 released from 
C6 glioma cells in vitro. Isoproterenol (IPT) is a drug that mimics the actions of the 
neurotransmitter norepinephrine. IPT in the presence of IL-1 causes a synergistic 
stimulation of lL-6 release from the C6 glioma cells. In addition, SRIF-14 and SRIF-28 
inhibited the lL-1 plus IPT synergistic induction of lL-6 release.
y-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter located in the 
CNS. It is one of several amino acids that play a part in regulating the nervous system. 
GABA is formed from glutamic acid, one of the traditional amino acids. When activated 
the GABAA receptor causes an increase in the net influx of Cf ions, which causes 
hyperpolarization of the neuron. Hyperpolarization of the neuron inhibits the action of 
excitatory neurotransmitters by raising the threshold for the onset of action potentials.
We decided to investigate GABA ability to inhibit the release of IL-6 by IL-ip.
iv
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GABA inhibited the basal and IL-ip stimulated release of IL-6. Further GABA is shown 
to inhibit the synergistic release of IL-6 by IL-IB and the P-adrenergic receptor agonist 
IPT.
Previously shown LPC induces the release of IL-6 from the C6 glioma cell line. This 
induction of IL-6 suggests that LPC acts as a second messenger o f IL-1 P in the C6 cell 
line. As with IL-ip, LPC-18 and IPT together will produce a synergistic release of IL-6.
This increased release can be inhibited by the addition of SRIF-14.
To better understand the signal pathways of IL-1 P that results in the release of IL-6 
we used the inhibitors SP600125 and SB203580. SB203580 is a p38 MAPK inhibitor 
that targets the p38a and p38p2 kinases, while the p3SP kinase exhibits only partially 
sensitivity. The inhibitor SP600125 targets the INK kinase.
The SB203580 kinase inhibitor resulted in the reduction of IL-6 below detectable 
levels both basally and with the addition of IL-1P or LPC. SP600125 on the other hand 
showed no inhibition of the release of IL-6 for either IL-ip or LPC.
It may be possible to reduce the high levels of the cytokine IL-6 by increasing the 
amount of SRIF in the CNS back towards normal levels. We suggest that the ability to 
lower the concentration of lL-6 maybe therapeutic for AD patients. Providing a new 
method of treatment for AD.
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CHAPTER 1
INTRODUCTION 
Hypothesis Statement 
The release of IL-6 is an important facet of the immune system and regulation of the
neuroendocrine system. Its release has ramifications on a number of factors in the CNS. 
When its release is not properly regulated as in AD and other neurodegenerative 
disorders it can cause damage to surrounding tissue and further the progression of the 
disease. Previous studies show that the release of IL-6 from the C6 cell line can be 
increased by a number of neurotransmitters such as norepinephrine and epinephrine. In 
this study, I am investigating the neurotransmitters SRIF-14, SRIF-28, GABA and the 
SP600125 and SB203580 inhibitors. I hypothesize that the neurotransmitters SRIF-14, 
SRIF-28 and GABA will reduce the release of IL-6 from the C6 cell line. Further I 
hypothesize that the SB203580 p38 MAPK kinase inhibitor will reduce the release of IL- 
6, while the SP600125 INK kinase inhibitor will not affect the release of IL-6 from the 
C6 cell line. The findings from this study will further elucidate the IL-1 P signal 
transduction pathway for the stimulation of IL-6 from the rat C6 glioma cell line. More 
importantly the ability to regulate IL-6 in the CNS of AD patients may prove to have 
therapeutic value in slowing down the progression o f this disease.
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Immune System
There are two main components of the immune system, the humoral immime
response and the cell-mediated immune response. The humoral or antibody response 
involves the concerted action of two different classes of white cells or lymphocytes, 
which are the B cells and T cells. When B cells are exposed to foreign substances or 
antigens they multiply and begin producing immunoglobulin proteins (antibodies), which 
are then secreted into the bloodstream and bind to the target antigen. The T cells have 
three different classes: killer T cells that destroy target cells, helper T cells that stimulate 
the maturation of antigen-stimulated B and T cells and suppressor T cells that block the 
response of the helper T cells. The T cells also regulate the inflammatory response by the 
secretion of specific interleukin proteins.
The cell-mediated immune response has two forms of action that involve the use of 
different types of T cells. The specific death T cells. To, can secrete interleukins that 
activate macrophages after interaction with an antigen. This interaction produces a slow 
inflammatory response. The second form of action involves the killer T cell, Tk , which 
will cause the lysis of target cells with antigen bound to them.
Neuroendocrine System
The neuroendocrine system is made up of specialized neuroendocrine cells found in 
the hypothalamic region of the brain that can regulate the secretion of hormones from the 
pituitary gland (Bowman, 1999). The hypothalamic-median eminence-anterior pituitary 
neuropeptide system and the hypothalamic-posterior pituitary system form the pathways 
by which the brain and neuroendocrine secretions reach their targets. The hypothalamus 
is essential in the maintenance of homeostasis and integration of behavioral patterns. It
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has reciprocal neural connections with much of the cerebral hemispheres and brainstem. 
In addition many of the hypothalamic areas contain neurosecretory cells that can regulate 
the release of pituitary tropic hormones through a vascular route to the anterior pituitary 
gland, or through a neural route to the posterior pituitary (Strand, 1999).
There are two main components to this system. The frrst component is the 
magnocellular neuroendocrine system made up of large cells in the supraoptic nucleus 
(SON) and the paraventricular nucleus (PVN) of the hypothalamus. The axons from 
these cells pass through the infundibulum to terminate in the posterior pituitary gland, 
where they release their secretions, oxytocin (OT) and vasopressin (VT), into the venous 
circulation (Strand, 1999).
The parvocellular neurosecretory system forms the second component. The axons of 
cells in several parts of the hypothalamic region, including the preoptic area, 
ventromedial, dorsomedial, posterior hypothalamic, premammillary and suprachiasmatic 
nuclei release their stimulating or inhibiting secretions into the vascular system of the 
median eminence (ME).
Interleukin Cytokines 
Cytokines are low molecular weight proteins secreted by a cell into the extracellular 
fluid where they exert their effects on the same cells (autocrine activity) or on 
neighboring cells (paracrine activity) by interacting with specific receptors (Balkwill, 
1991). Through these actions cytokines can mediate immune responses as well as affect 
neuroendocrine function and hormone secretion. The cytokine family of peptides 
consists of the interleukins (1 to 18), tumor necrosis factor-a (TNF-a) and -P, colony 
stimulating factor (CSF), interferons, transforming-growth fiactors-P, chemokines and
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growth factors (Casey, 1999). As a subset of the cytokine 6m ily, the interleukins 
function as inflammatory cytokines by promoting cell growth, differentiation and 
functional activation. IL-4 is the exception that functions as an anti-inflammatory 
cytokine. These inflammatory cytokines include interleukin-1 (IL-IP), interleukin-2 (IL- 
2), interleukin-6 (IL-6) and tumor necrosis factor-a. They are made chiefly by activated 
macrophages. These four cytokines activate the HPA axis at the hypothalamic, pituitary, 
and adrenal level. The receptors for the cytokines are found on hypothalamic 
neuroendocrine cells and on pituitary corticotrophs (Strand, 1999). These factors are 
known to cause swelling and inflammation of the surrounding tissue and play an 
important role in the acute phase response to infection. Elevated levels of IL-1, IL-6 and 
TNF-a are present in the CNS in a number of neurodegenerative diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD). Current evidence suggests that 
the elevated levels of IL-1, IL-6 and TNF-a in the senile plaques of AD and 
neurochemical lesions of PD are important factors in the development and progression of 
the disease state. These increased levels of cytokines may cause a self-propagating 
inflammatory process contributing to senile plague formation and disease progression.
The interleukin-1 (IL-1) family of proteins currently comprises IL-1 a , IL-ip and the 
IL-1 receptor antagonist, IL-lra (O’Neill, 1994). The interleukins IL-1 a  and IL-ip are 
synthesized as precursors without leader sequences. The molecular weight of each 
precursor is 31 kDa (Dinarello, 1997). IL-1 a  and IL-1P are processed to their 'hnature" 
forms of 17 kDa molecular weight polypeptides by specific cellular proteases. The 
precursor of IL-1 a , (proIL-la), can be processed in one of two ways. ProIL-la can be 
cleaved by extracellular proteases after cell death, or cleaved following activation of the 
calcium dependent, membrane-associated cysteine proteases known as calpains. The
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5precursor of IL-1 P (proIL-iP) on the other hand is processed to its mature form by 
caspase 1, also called IL-ip converting enzyme (ICE). The final member of the family, 
IL-lra, has two isofbrms. One is secreted while the second is intracellular. They act as 
competitive IL-1 antagonists, preventing both IL-1 agonists from binding the IL-1 
receptors, inhibiting their biological activity. The primary amino acid homology of 
mature human IL-1 P to IL-lra is 26%, which is greater than that between IL-1 a  and IL- 
IP (Dinarello, 1997).
There are currently two IL-1 receptors recognized. The type I (IL-IRI) is the major 
receptor on the cell surface, binding both isoforms of IL-1, and transduces a signal to the 
cell nucleus via activation of the nuclear transcription factor NF kB (Vitkovic, 2000). It 
is a 80-kDa high-affmity receptor found on several cell types. It works in conjunction in 
some cell types with the IL-1 receptor accessory protein (IL-IR AcP), which has a 
molecular mass of 66 kDa. The IL-IR AcP increases the binding affinity of both IL-ip 
and IL-ip but does not specifically bind either IL-1 agonist. In the immune system, the 
type 1 IL-1 reeeptor is predominantly expressed on T cells and fibroblasts, whereas the 
type II IL-1 receptor is found on B cells and macrophages (Dantzer, 1997). It has been 
shown that the type I IL-1 receptor mediates lL-1 P-induced fever. The type II IL-1 
receptor does not transduce a signal when bound by an active ligand. It therefore acts as 
a decoy receptor for IL-1 and can negatively regulate the biological activity of IL-1 along 
with IL-lra.
Interleukin-6 (IL-6) is a cytokine with a variety of biological functions and can
function as either a chemokine or an inflammatory cytokine. It plays a critical role in B 
cell differentiation, T-cell activation and is a key mediator of the acute phase response 
(Akira, 1993). Among its other actions IL-6 acts as an inhibitor of TNF-a, another
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important inflammatory cytokine induced by lipopolysaccharide (LPS). IL-6 acts as a 
component of the negative feedback for TNF-a. IL-6 has a wide range of functions in 
the CNS and in certain disease states. The molecular mass of human IL-6 ranges from 
21-28 kDa and is 58% identical to rat IL-6.
IL-6 binds to its receptor to form the biologically active IL-6 receptor complex (IL- 
6rc), which is made up of two membrane glycoproteins and IL-6. The two membrane 
glycoproteins are the ligand binding a-subunit (IL-6r or gp80) and the non-ligand 
binding, signal transducing P-receptor subunit (gpl30). The gpl30 glycoprotein cannot 
bind IL-6 itself but it confers high affinity binding and is responsible for the signal 
transduction. Several other cytokines and hormones share the gpl30 subunit as a 
component for signal transduction. The activation of gpl30 allows the JAK family of 
enzymes to phosphorylate the tyrosine residues of the intracellular part of the gpl30 
subunit.
Tumor necrosis factor-a (TNF-a) is an important inflammatory mediator with many 
biological functions. It plays a vital function in the immune system. When released, 
TNF-a stimulates an increase in the number of B cells, initiation of leukocyte adherence 
to vascular endothelial cells, and stimulation of other mononuclear phagocytes to secrete 
lL-1, lL-6 or IL-8 (Prescott, 1996). It can act on the hypothalamus to induce fever and is 
cytotoxic to tumor cells.
TNF-a has two transmembrane receptors of 55 kDa (TNF-rl) and 75 kDa (TNF-r2). 
TNF-rl is the major receptor for TNF-a and binding of TNF-a to the TNF-rl leads to 
apoptosis, tissue necrosis, and activation of nonspecific immunity. The TNF-r2 has been 
implicated in several biological activities including T cell cytotoxicity, thymocyte 
growth, and the stimulation of granulocyte colony-stimulating factor secretion.
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Interleukin-ip Signal Transduction Pathways 
The binding of IL-1 P to the IL-IR forms the IL-IR AcP complex. This complex 
activates a cascade of kinases leading to the activation of the transcriptional factors NF-
kB and AP-1. The first step in this process is the association of the IL-1 receptor 
associating kinase (IRAK) with the IL-IR AcP figure (4). IRAK does this by forming a 
complex with the adapter protein MyD88 and the Tollip protein. Upon stimulation with 
IL-1 MyDSS recruits the IRAK/Tollip complex to the IL-IRI complex. IRAK is then 
phosphoiylated and released from the IL-IRI complex. The phosphoiylated IRAK 
subsequently interacts with TRAP6 a member of the TNF receptor-associated factor 
family (Daun, 2000). TRAF6 subsequently associates with the mitogen-activated protein 
(MAP) kinase complex (TAKl/TABl) giving rise to a bifurcation of the IL-1 signaling 
pathway leading to NF-kB and AP-1 activation.
To activate NF-kB the TRAF6/TAK1 /TAB1 complex stimulates the NF-kB-inducing 
kinase (NIK). NIK forms a complex with two kinases, IKKa and IKKp. IKKa and 
IKK|3 then phosphorylates I-kB, releasing NF-kB which is translocated to the nucleus 
and activates transcription of kB binding site. In a separate pathway the evolutionarily 
conserved signaling intermediate in Toll pathways (ECSIT) can interact with TRAF6 to 
activate the processing of MEKKl. The processed MEKKl can now activate the IKKa 
and IKKp. IKKa and IKKP, which then follows the same pathway as described above.
To activate AP-1 the TRAF 6/T AK 1/TABl complex activates the MEK3/MEK6 
complex. The MEK3/MEK6 then phosphorylates the p38 mitogen-activated protein 
(MAP) kinase. This kinase then activates c-JUN which is translocated to the nucleus and 
activates transcription of AP-1. In a separate pathway ECSIT can interact with TRAF6 to 
activate the processing of MEKKl. The processed MEKKl can now activate the
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8MEKK3/MEKK6 complex, which then follows the same pathway as described above.
In a separate pathway independent of MyD88 and IRAK the second messenger 
diacylglycerol (DAG) is produced by the breakdown of phosphatidylcholine (PC) by a 
phosphatidylcholine-specific phospholipase C (PC-PLC). Intracellular DAG activates 
protein kinase C (PKC). The exact role of this pathway is not known at this time, 
however there is some evidence that this pathway may negatively regulate IL-6 synthesis.
In a third, separate, pathway IL-ip stimulates phospholipase A% (PLA2) activation to 
hydrolyze phosphatidylcholine, forming lysophosphatidylcholine-18 (LPC-18) and 
arachidonic acid (AA). LPC induces the release of IL-6 from the C6 glioma cell line. 
This induction of IL-6 suggests that LPC acts as a second messenger of IL-1 P in the C6 
cell line.
Somatostatin
Somatostatin (SRIF) is a multifunctional hormone inhibiting the release of many 
pituitary, pancreatic, and gut hormones, as well as the exocrine secretions of the 
gastrointestinal tract (Strand, 1999). It mainly exerts an inhibitory effect on endocrine 
and exocrine secretion and on the response of various cell types to endocrine stimulation 
(Ferone, 1999). It inhibits the release of growth hormone (GH), thyroid stimulating 
hormone (TSH) and prolactin (PRL) by the anterior pituitary. There are two forms of 
human somatostatin, SRIF-14 and SRIF-28. The primary function of SRIF is inhibitory 
and acts as an anti-inflammatory substance. There is evidence that SRIF may act as a 
feedback mechanism in the immune system by regulating the degree of tissue 
inflammation. In Alzheimer’s disease (AD) the levels of both SRIF and its receptors 
(especially high-affmity type 1) are decreased with the largest reduction in areas most
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affected by AD. The degree of cognitive impairment has been correlated to the loss of 
SRIF and its receptors.
In rats and humans, SRIF is derived from a single gene to form preprosomatostatin. 
This is then processed in the cell to form either SRIF-14 or SRIF-28. The two forms of 
SRIF are stored in separate compartments in the cell until released. The SRIF-28 can be 
reprocessed to form SRIF-14 if needed, the bond between the 13^ and 14^ amino acid is 
broken to form a single protein of SRIF-14. The ratio of SRIF-14 to SRIF-28 found in 
the cell is approximately 3:1, but SRIF-28 is 3 to 8 times more potent than SRIF-14 in the 
inhibition of the release of GH. SRIF-14 shows a slightly higher binding affinity for the 
receptor subtypes 1-4 while SRIF-28 shows a 10 fold higher affinity for the subtype 5 
receptor (Benali, 2000). The inhibitor effects of SRIF-28 are generally more potent for a 
number of biological end points.
There are five transmembrane G protein-coupled receptor subtypes that bind SRIF-14 
and SRIF-28 with high affinity. The subtypes 1 and 2 are distributed throughout most of 
the CNS. Subtype 3 is found in the motor neurons of the brainstem. In the C6 glioma 
cell line the major SRIF receptor expressed is the subtype 2 receptor, while the subtype 5 
receptor is not expressed. All five identified SRIF-receptors can stimulate 
phosphatidylinositol metabolism, are coupled to inhibitory G proteins, and may inhibit 
adenylyl cyclase (Akbar, 1994). The five receptor subtypes are 42-60% identical to each 
other. They are distributed in all the major brain regions, with the highest concentrations 
in the cerebral cortex, intermediate concentrations in the hypothalamus, thalamus, 
amygdala, and hippocampus, and the lowest concentrations in the mid- and hindbrain 
(Strand, 1999). Once SRIF binds to its receptor it inhibits adenylate cyclase, Ca^  ^fluxes 
and hyperpolarizes cell membranes by opening various channels. It has been shown
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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that the SRIF receptor subtypes have unique tissue distributions.
y-Aminobutyric Acid 
y-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter located in the 
CNS. GABA is found primarily iu the CNS with httle or none located in any other body 
tissue. It is one of several amino acids that play a part in regulating the nervous system.
GABA is formed from glutamic acid, one of the traditional amino acids. It mainly exerts 
an inhibitory effect through its primary receptor, GABA a , which forms a functional 
chloride channel. When activated the receptor causes an increase in the net influx of Cl' 
ions, which causes hyperpolarization of the neuron. Hyperpolarization of the neuron 
inhibits the action of excitatory neurotransmitters by raising the threshold for the onset of 
action potentials.
GABA has two receptor subtypes in the CNS, which have been grouped by their 
pharmacological action. The GABAa receptor-ion channel complex is a 
heteropentameric glycoprotein of approximately 275 kDa. The receptor complex is 
composed of five different classes of polypeptide subunits (a , P, y, 8, and p). In addition 
a number of isofbrms have been found so that 15 subunits have been identified. The 
expression of the subunits for the GABAa receptor has been found to vary from one 
region of the brain to another and confers a diversity of pharmacological responses. The 
GABAa receptor complex forms a C f ion channel and has binding sites for 
benzodiazepines, barbituartes, and a steroid site. Benzodiazepines and barbituartes can 
allosterically modulate the receptor-channel complex. The GABAg receptor is less 
common in the CNS and is coupled to Ca^ and channels. This receptor decreases Ca^ 
flux and increases flux using second messenger systems.
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Role of Cytokines in Inflammation and Nenrodegeneration
Inflammation is characterized by the migration of leukocytes, increased blood flow 
and capillary permeability to immune cells to the area of infection or injury. Brain 
trauma can be caused by a number of factors such as viral inflection, neurotoxic injury,
loss of oxygen or nutrients and senile plaques caused by Alzheimer disease (AD). The 
cytokines IL-ip, TNF-a and IFN-y can increase the damage in the brain when they are 
not strictly controlled. Cytokines activate glial cells, which in turn produce more
cytokines. The resulting brain inflammation can cause the loss of neuronal function.
Current evidence suggests that plaque-associated activated glia and cytokines are 
important factors in the development and progression of the neuropathological hallmarks 
of AD. In AD an inflammatory response is mounted in which activated micro- and astro­
glia and their secreted inflammatory mediators and matrix constituents elicit the 
transformation of diffuse into neuritic plaques, which secondarily may induce further 
tissue damage (Heininger, 1999). The activated microglia are found to surround the 
neuritic plaques in a “halo” effect. The main generators of IL-1 in the brain are activated 
microglia. In AD patients as compared to age match controls there is a 6-fold increase of 
activated immunoreactive IL-1 microglia in the CNS. IL-1 expression further correlates 
with the distribution of neuritic plaques located in the brain. IL-1 P has been shown to 
stimulate the production of IL-6, another cytokine that is important in the inflammatory 
response and in the progression of AD. Both IL-1 and IL-6 levels in the CNS are 
increased in the early stages of AD and correlate with the severity of dementia in patients. 
Further, the amyloid precursor protein (APP) is upregulated by IL-1 and IL-6. The 
processing of APP to form the P-amyloid protein (PA) that forms the plaques has been 
linked to activated astrocytes and microglia. Current evidence shows that microglial cells
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are directly engaged in the production of the P-amyloid protein. The first deposits of the 
PA protein appear in the plasma membranes and altered cytoplasmic membranes of 
microglial cells. Their role iu processing the PA is emphasized by the inability to detect 
the APP mRNA in microglial cells.
AD is a systematic disease that causes alterations in a wide range of systems in the 
CNS. The GABAergic system has been described as least affected with what appears to 
be area-specific hippocampal decrements of the GABA^ and GABAg receptors 
(Heininger, 1999). The somatostatinergic system shows serious alterations from the 
norm, SRIF is a multifunctional hormone, which acts primarily as an inhibitory protein.
In AD patients the degeneration of somatostatinergic intemeurons is present in several 
CNS locations. This degeneration causes a loss of SRIF-like immunoreactivity and an 
overall decrease in the SRIF concentrations of the CNS of AD patients. Likewise, there 
is a decrease in SRIF receptors. The degree of cognitive impairment of AD has been 
correlated to this loss of SRIF. As will be shown SRIF can inhibit the production of IL-6 
by IL-1 p. This finding may be of therapeutic value to AD patients in the future.
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CHAPTER 2
MATERIALS AND METHODS 
Chemicals and Reagents
The 7TD1 hybridoma cell line was obtained from Dr. J. Van Snick, Ludwig Institute 
(Brussels, Belgium). It is a mouse tumor cell designed to detect the presence of IL-6.
The C6 glioma cell line was obtained from the American Tissue Type Culture Collection 
(Rockville, MD). It is a rat tumor astrocyte cell line used to produce the interleukin-6 
protein for detection. Recombinant rat interleukin-ip (IL-lp) was obtained from 
PeproTech Inc. (Rocky Hill, NJ). Recombinant murine interleukin-6 (IL-6) was obtained 
from R & D Systems (Minneapolis, MN). (-)-isoproterenol (IPT), (S)-(-)-propranolol 
(PRO), GABA (y-amino-n-butyric acid), recombinant somatostatin-14 (SRIF-14), 
recombinant somatostatin-28 (SRIF-28), isopropanol (reagent grade), MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tétrazolium bromide), streptomycin sulfate, penicillin 
G, gentamycin sulfate and P-mercaptoethanol were obtained from sigma Chemical Co. 
(St Louis, MO). l-capryl-2-hydroxy-sn-glycero-3-phosphocholine (LPC-10), 1- 
myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC-14), 1 -palmitoyl-2-hydroxy-sn- 
glycero-3-phosphocholine (LPC-16), 1 -stearoyl-2-hydroxy-sn-glycero-3-phosphocholine 
(LPC-18), l-arachidoyl-2-hydroxy-sn-gly cero-3-phosphocholine (LPC-20) were obtained 
from Avanti Polar Lipids Inc. (Alabaster, AL). SB203580 and SP600125 were obtained 
from Calbiochem (San Diego, CA). RPMI-1640, fetal bovine serum (PCS), horse serum
13
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(HS), fungizone and trypsin were obtained from Gibco (Grand Island, NY). Fetal calf 
serum (FCI) was obtained from Hyclone (Logan, UT). Sodium Bicarbonate, sodium 
phosphate and trypan blue were obtained from Fisher Scientific (Santa Clara, CA).
C6  Glioma Cell Culture 
The C6  glioma cells were maintained in continuous culture in a humidified 
atmosphere of 5% C0 2 -9 5 % air at 37 °C in RPMI-1640 medium supplemented with
7.5% horse serum (HS), 2.5% fetal calf serum (PCS) and antibiotics (7.5 pg/mL 
streptomycin, 15 pg/mL gentamycin, 19 |Xg/mL penicillin and 0.6 pg/mL fungizone). 
After 3 days in culture the C6  cells were removed from the tissue culture flask using 
0.25% trypsin in phosphate-buffered saline. The C6 cells were then centrifuged at 400 
rpm for 5 minutes, the trypsin was removed and the cells were resuspended in the C6 
culture medium. The C6 cells were counted using a hemacytometer and were placed 
either back into continuous culture at 1.0 x 10  ^cells per 25 cm^ flask, or were dispersed 
into a 96-well tissue culture plates at 1.0 x 10^  cells/well with C6 medium for 
experimental release studies using the 7TD1 bioassay.
C6 cells were allowed to adhere to the plates for 24 hours, after which the cells were 
rinsed twice with 200 pi serum free RPMI-1640. The C6 cells were then exposed to 
vehicle (200pL serum free RPMI-1640/well), with and without IL-ip and other agents 
for 24 hours. When inhibitors were used the cells were pretreated with the appropriate 
inhibitor for 1 hour in serum free RPMI-1640 and then exposed to the compounds of 
interest with and without IL-1 p. After 24 hours the conditioned media was transflsrred to 
a new 96-well plate, which was then stored at 4 °C until measurements for IL-6 by the 
7TD1 bioassay.
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7TD1 Bioassay for IL- 6  
The 7TD1 cells were maintained in continuous culture in a humidified atmosphere of 
5% COz-95% air at 37 °C in 10 mL RPMI-1640 supplemented with 5% FCI (Fetal Clone 
I; Hyclone, Logan, UT), 50 pM P-mercaptoethanol, 5 pg/mL rmIL-6 , and antibiotics. 
After 3 days in culture the 7TD1 cells were removed from the tissue culture flask using 
trituration and approximately 1.0 x 10^  cells were distributed in a 25 cm  ^flask (Greiner) 
for continuous culture, or were dispersed into a 96-well tissue culture plates at 4.0 x 10^  
cells/well with SR-RPMI medium for experimental release studies using the 7TD1 
bioassay.
We used the IL-6 -dependent 7TD1 hybridoma bioassay as described in (MacLeod et
al., 1993), with minor modifications to quantify the accumulation of IL-6 in the C6 
conditioned media. Conditioned media (20 uL) was cultured in 96 well tissue culture 
plates in duplicate in 180 pL RPMI-1640 supplemented with 5% FCI, 50 pM P- 
mercaptoethanol, and antibiotics in the presence of 4,000 7TD1 cells for 72-96 hours. 
Tétrazolium salt (MTT) was used to determine the growth of the 7TD1 cells. MTT is 
cleaved in active mitochondria to form a dark blue formazan crystal. After 72-96 hours 
20 pL of 5 mg/mL MTT was added to each well for 3.5 hours. 150 pL of medium was 
removed from each well after the 3.5 hours and the dark blue crystals were dissolved by 
the addition of 150 pL of 0.04 M HCL/isopropanol to form a dark colored liquid. The 
plates were stored overnight in the dark after which the optical densities were determined 
by a microelisa instrument using a test wavelength of 570 nm and a reference wavelength 
of 630 nm (Dynatech MR5000). For each assay a standard curve of rmIL-6 (0.5 to 64 
pg/well) was generated. The data are formed from treatment groups each of which 
consists of 4 observations per group and are presented as the mean ± SEM.
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CHAPTER 3
RESULTS
7TD1 Bioassay Standard Curve 
The bioassay standard curves are shown in (fig. 3 and 4). A line-of-best-fit equation 
was obtained from a dose response curve of rmIL-6 and optical density. In figure, 
amounts of rmIL-6 greater than 64.0 pg/well do not provide further linear increase in the 
optical density values. The linear regression equation is easily solved for the x-axis 
values with a correlation coefficient of >0.99. The minimum amount of IL-6 detectable 
in this assay was 0.5 pg/well. Samples to be tested need to be diluted properly so that the 
values generated will fall into the linear portion of the standard curve.
In some cases a logarithmic line-of-best fit equation will generate a better correlation 
coefficient than a linear regression equation. The values of IL-6 from the logarithmic 
equation are only calculated on the linear portion of the curve. As with the linear 
regression equation samples are diluted properly so that the values generated fall into the 
linear portion of the standard curve. The logarithmic equation is easily solved for the x- 
axis values with a correlation coefficient of >0.95. The minimum amount of IL-6 
detectable in this assay was 0.5 pg/ml. The linear regression equation is used more 
frequently to generate the line-of-best fit.
16
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Rat Interleukin-ip Dose Response 
IL-IP increased the release of IL- 6  in a concentration dependent manner (fig. 5). The 
cells were allowed to incubate for 24 hours. The release of IL- 6  by the C6  cells was 
maximal between 5 and 100 ng/ml IL-ip. For most experiments a concentration of 50 
ng/ml IL-ip was used.
Effects of Isoproterenol and IL-ip on IL-6 Release 
Isoproterenol (IPT) is a P-adrenergic receptor agonist that activates adenylyl cyclase
to increase cAMP concentrations mimicking the actions of norepinephrine. (Fig. 6) 
shows that there was a 3-fold induction of IL-6 release from the C6 cells when IPT (10 
pM) was added to IL-lp (5 to 100 ng/ml). For example, at IL -ip (50 ng/ml) a 
concentration of 470 ± 45 pg/well of IL-6 was measured. In the presence of IPT and IL- 
Ip there was a synergistic increase of IL-6 release of 1592 ± 104 pg/well. This effect can 
be blocked by the use of propranalol (PRO), which antagonizes the IPT binding to the P- 
adrenergic receptor.
Somatostatin Effect on 7TD1 Cell Line 
To rule out the possibility that SRIF has any negative effects on the 7TD1 cell line 
itself, SRIF-14 and -28 were added separately to the 7TD1 bioassay standard curve and 
compared to a normal standard curve (fig. 7). The concentration of SRIF was calculated 
as the amount that would be present in the 7TDI bioassay experiment when a maximum 
concentration o f200 nM was used in the C6  cell line. All three standard curves were 
similar suggesting that SRIF has no negative effects on the 7TD1 cell line itself.
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Inhibition of IL- 6  Induction by Somatostatin 
Somatostatin (SRIF) has two forms SRIF-14 and SRIF-28. SRIF is multifunctional 
hormone, inhibiting the release of many pituitary, pancreatic, and gut hormones. The 
primary function of SRIF is inhibitory and acts as an anti-inflammatoiy substance by 
inhibiting adenylyl cyclase. We decided to investigate the ability of SRIF-14 and -28 to 
inhibit the IL-ip induction of IL- 6  release. In similar SRIF dose response experiments, 
both forms of SRIF are shown to inhibit the release of IL- 6  by IL-ip in the C6  cell line m 
vitro (fig. 8 and 11). Further both SRIF-14 and SRIF-28 inhibited the synergistic release 
of IL- 6  by IL-ip and IPT (fig. 10 and 13). Both forms of SRIF showed a maximum 
inhibition of IL- 6  at 200 nM. SRIF-14 and -28 appears to possess similar ICgo for the 
inhibition of IL-6 in the C6 cell line in vitro (fig. 14).
y-Aminobutyric acid Effect on 7TD1 Cell Line 
To rule out the possibility that G ABA has any negative effects on the 7TD1 cell line 
itself, GABA was added to the 7TD1 bioassay standard curve and compared to a normal 
standard curve (fig. 15). The concentration of GABA was calculated as the amount that 
would be present in the 7TD1 bioassay experiment when a maximum concentration of 
1000 nM was used in the C6 cell line. Both standard curves show a very close homology 
that suggests that GABA has no negative effects on the 7TD1 cell line itself.
Inhibition of IL- 6  Induction by y-Aminobutyric acid 
y-Aminobutyric acid (GABA) is an inhibitory neurotransmitter located in the CNS.
GABA is found primarily in the CNS with little or none located in any other body tissue. 
We decided to investigate GABA ability to inhibit the release of IL-6 by IL-ip. As
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shown in (fig. 16) GABA inhibited the basal and IL-ip sthnulated release of IL-6 .
Further GABA is shown to inhibit the synergistic release of IL- 6  by IL-IB and the P- 
adrenergic receptor agonist IPT (fig. 18).
Proposed Second Messenger of IL-ip 
Lysophosphatidylcholine-18 (LPC-18) is a proposed second messenger of IL-ip in
the C6 cell line. A number of different chain length forms of LPC-18, which is the 
natural form, were used. As shown in (fig. 19), LPC induces the production of IL- 6  hom 
the C6  cell line in vitro. As with IL-ip, LPC-18 and IPT together will produce a
synergistic release of IL-6 (fig. 20). This increased release can be inhibited by the 
addition of SRIF-14 shown in (fig. 21).
SB203580 Effect on 7TD1 Cell line
To rule out the possibility that SB203580 has any negative effects on the 7TD1 cell 
line itself, SB203580 was added to the 7TD1 bioassay standard curve and compared to a 
normal standard curve (fig. 22). The concentration of SB203580 was calculated as the 
amount that would be present in the 7TDI bioassay experiment when a maximum 
concentration of 10 uM was used in the C6 cell line. Both standard curves show that 
SB203580 does have an effect on the 7TD1 cell line but not enough to account for the 
large reduction shown in figures 24-27.
IL-ip Signal Transduction Pathways
To better understand the signal pathways of IL-lp that results in the release of IL-6 
we used the inhibitors SP600125 and SB203580. SB203580 is a p38 MAPK inhibitor
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that targets the p38a and p38^2 kinases, while the p38P kinase exhibits only partially 
sensitivity. The inhibitor SP600125 targets the JNK kinase. As shown in (fig. 24), the 
SB203580 kinase inhibitor resulted in the reduction of IL- 6  below detectable levels both 
basally and with the addition of IL-ip. SP600125 on the other hand showed no inhibition
of the release of IL-6 (fig. 25).
To gain further understanding of the signal pathway of LPC-18, we used the proposed 
second messenger LPC-18 and the p38 kinase inhibitor SB203580 as shown in (fig. 26). 
In a similar effect seen when used with IL-P, SB203580 resulted in nondetectable levels
of IL-6 both basally and in the presence of LPC-18. The SP600125 JNK kinase inhibitor 
as with IL-ip showed no inhibition of the release of IL-6 when used with LPC-18 (fig. 
27).
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CHAPTER 4
DISCUSSION 
Inhibition of IL- 6  Production
We have demonstrated that IL-ip stimulates the release of IL-6 from the rat C6 
glioma ceU line w W/yo. IL-ip also acts synergisticahy with IPT to increase the release
of IL-6. IPT is a P-adrenergic agonist that stimulates the production of cAMP in the cell 
and thus mimics the effects of the monoamine norepinephrine. The monoamines 
epinephrine and dopamine have previously been shown to synergisticahy act with IL-ip 
to stimulate the release of IL-6, but to a lesser effect than norepinephrine.
IL-6 release is modulated by a number of CNS-acting neurotransmitters. The 
neurotransmitters SRIF-14, -28 and GABA act primarily as inhibitors in the CNS. SRIF- 
14 and -28 have five transmembrane G protein-coupled receptor subtypes with 
distributions in all the major brain regions and a unique tissue distribution. The subtypes 
1 and 2 are distributed throughout most of the CNS while subtype 3 is found in the motor 
neurons of the brainstem. In the C6 rat glioma cell line the major SRIF receptor 
expressed is the subtype 2 receptor, while the subtype 5 receptor is not expressed. The 
subtypes 1-4 show a slightly increased affinity for SRIF-14 while subtype 5 shows a 10 
fold higher aSmity for SRIF-28 (Benali, 2000).
This study demonstrates that IL- 6  release fi-om the C6  glioma cell line can be 
inhibited by neurotransmitters that reduce the intracellular levels of cAMP. Using a
21
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maximal concentration of 50 ng/ml of IL-ip, the levels of IL- 6  produced were 
significantly inhibited by the addition of 200 nM of SRIF-14 or SRIF-28. SRIF-14 
inhibited the release of IL- 6  to basal levels in the presence of a maximal dose of IL-ip.
In contrast, SRIF-28 showed a 65% reduction of IL- 6  release 6 om C6  rat glioma cells. 
Further IL-1P + IPT produces a synergistic production of IL-6 . SRIF-14 reduced this 
production by 82% while in contrast SRIF-28 showed a 43% inhibition of IL-6 . It 
appears that SRIF-14 is a slightly more efficacious inhibitor than SRIF-28 in the C6  rat 
glioma cell line.
The neurotransmitter GABA opens a functional chloride channel when bound to its 
receptor. GABA inhibits the actions of excitatory neurotransmitters by raising the 
threshold for the onset of action potentials for cells by increasing the net influx of Cl' 
ions. GABA inhibited the production of IL-6 induced by a maximal concentration of 50 
ng/ml IL-lp: 1 mM GABA reduced the stimulated release of IL-6 by 85%. The 
synergistic release of IL-6 by IL-ip and IPT is inhibited by 1 mM GABA by 55%.
To further elucidate the signaling pathway of IL-ip and LPC we used the inhibitors 
SP600I25 and SB203580. SP600125 inhibits the JNK kinase that is postulated to be 
involved in the release of IL-6. The SB203580 is a p38 MAPK kinase inhibitor that 
selectively targets the p38a and p38p2 kinases, but has only minimal affects on the p3SP 
kinase. Results show that the SB203580 inhibitor blocked the IL-ip and LPC-18 
stimulation of the IL-6 release from C6 rat glioma cells. This indicates that the P38 
MAP kinase is an essential component of the intracellular signaling pathway activated by 
either IL-ip or LPC-18. The SP600125 inhibitor showed no reduction in the levels of 
IL- 6  released fiom the C6  cell line. This shows that the JNK kinase is not involved 
in the IL-ip or LPC-18 signaling pathway as previously thought.
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LPC-18 is a proposed second messenger of IL-ip. LPC-18 can induce the release of 
IL- 6  6 om the C6  cell line and IL-ip stimulates the production of this lysophopholopid. 
LPC-18 is formed by the breakdown of phosphatidylcholine by phospholipase A: after 
IL-1P binds to its receptor. The addition of LPC-18 resulted in a similar but lesser 
release o f IL- 6  ftom the C6  cell line compared to IL-ip. LPC-18 mimicked the actions 
of IL-ip in many aspects; its stimulation of IL- 6  release was inhibited by the same 
neurotransmitters (SRIF-14, -28 and GABA) that inhibited the IL-ip stimulated release 
of IL-6. Further, the SB203580 and SP600125 kinase inhibitors resulted in the same 
actions when used in conjunction with IL-ip. SP600125 resulted in no reduction in IL-6 
release while SB203580 reduced IL- 6  release often to nondetectable levels.
The release of IL-6 is an important facet of the immune system and regulation of the 
neuroendocrine system. Its release has ramifications on a number of factors in the CNS. 
When its release is not properly regulated as in AD and other neurodegenerative 
disorders it can cause damage to surrounding tissue and further the progression of the 
disease. This study shows that IL-6 release can be regulated by a number of 
neurotransmitters and inhibitors. Because somatostatin reduction is one of the hallmarks 
of AD, its ability to regulate IL-6 release suggests that its réintroduction into the CNS of 
AD patients may prove to have therapeutic value in slowing down the progression of 
Alzheimer’s disease.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX I
USTOFHGURES
24
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
25
EXPERIMENTAL PROCEDURE 
Day 1
Plate C6  cells for a total volume 200 ^L with 1.0 x 10^  cells/well
Wash cells twice 
Add drugs, final volume 200 i^L
Day 3
Transfer media to new plate and store in the re&igerator
Day 6
Set up plates for duplicates o f experiment, concentrated and dilute 
Add 180 pL SF-RPMI to concehiated wells 
Add 150 (iL SR-RPMI to dilute wells 
Add 20 pL C6  media to conceitrated wells, total volume 200 pL 
Discard 50 pL media ûom concentrated wells 
Add 50 pL media 6 om concentrated wells to new set o f wells Air dilution, total volume
200 pL
Discard 100 pL media Aom dilute wells 
Plate 100 p i, 7TD1 cells for a fimd total volume of 200 pL wiA 4.0 x 10^  cells/weH
Day 9 —10
Add 20 pL MTT to each well 
Wait 3.5 hours 
Remove 150 pL media 
Add 150 pL 0.4 M HCL/Isopropanol 
Store plates in dark overnight
Day 1 0- 11
Read plates
Figure 1: General Schematic for the IL- 6  Bioassav. Genaal layout o f the experimental 
procedure used for A e ;noduction and quantification o f IL- 6  using A e C6  mouse tunmur 
cell line and the 7TD1 rat tumour ghal cell line.
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Figure 2: Interaction betwem a neuropeptide, the first messenger, with the surfice 
receptor, and the subsequent confmmational charge in the receptor that activates a 
membrane-bound intermediary, a G protein The G p ok in  activates membrane-bound 
enzymes that catalyze the poduction o f cytosolic second messengers to regulate a wide 
variety of cell functions. In many cases, there is signal transduction ooss talk betwear 
the d ifl^ n t second-messenger systems. PIPz (phoqAatid^linositol 4,5-b^osFhate), 
ATP (adenosine triphosphate), ADP (adenosine dqAosphate), CAL (calmodulin), DAG 
(diacylg^caol), IP3 (inositol tri{Aos;Aate) and cAMP (cyclic adenosine monofÂospate).
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Figure 3: 7 i D l cell bioassav standard curve with a linear regression line o f best fit 
equati<m. 7TD1 cells were cultured fbr 72-96 hours in the presence o f iocreasing 
amounts o f rmIL-6 (.5 to 64 pg/well). The optical density values were obtained with 
MTT, as described in text. The data are harmed ûom treatment groups incubated fbr 24 
hours each of whidi consists o f 4 observations per group and are presenW as the mean ±
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Figure 4: 7 IJUl cell bioassav KtandmrH curve with a loeanihmic line^f-best 6 t equadon. 
7ID1 ceUs were cultured &r 72-96 hours in the presence o f increasing amounts o f rmlL- 
6 (1 to 64 pg/well). The optical density values were obtained with M IT', as described in 
texL The data are formed from treatmait groups incubated fbr 24 hours each o f which 
consists o f 4 observatians per group and are presented as the mean ± SEM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
400
350
300
250
^ 2 0 0
150
100
50
0
0 25 50 75 100 125 150 175 200
IL-IB (ng/ml)
Figure 5: Ef&cts o f ÏL-16 on IL-6 release &om C6 glioma cells. C6 cells (100 x 10^  
cells/well) were incubated in the presence o f vehicle (SF-RPMI) and IL-ip (0 to 200 
ng/ml. The data are harmed horn treatment grou^ incubated fbr 24 hours each of which 
consists o f 4 observations per groiq) and are {«esaited as the mean ± SEM.
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Figure 6: Eflects o f IL-ip. Isoomterenol and Piomanolol on IL-6 release 8%n C6 
glioma cells C6 cells (1(X) x 10^  ceUs/well) were incubated in the presence o f vdiicle 
(SF-RPMI), IL-lp (0 to 100 ng/ml). IL-ip (0 to 100 ng/ml) + Isoproterenol (IPT) (10 
pM) and IL-ip (0 to 100 ng/ml) + IsofMroterenol (IPT) (10 pM) + Propranolol (PRO) (10 
pM). The data are formed from treatment g ro i^  incubakd har 24 hours each o f which 
consists o f 4 observations per group and are [xesented as the mean ± SEM.
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Figure?: Eûècts o f Somatostatin-14. Somalostatin-28 and IL-6 on 7TD1 cell bioassav 
standard curve. 7TD1 cells (8,000 cells/well) were incubated in the presence o f IX- 
7TD1 media, IL-6 (0.25 to 32 pg/well), Somatostatin-14 (SRIF-14) (200 nM) + IL-6 
(0.25 to 32 pg/well) and Somatostatin-28 (SRIF-28) (200 nM) + IL-6 (0.25 to 32 
pg/well). The data are formed from treatment groiq» incubated fbr 24 hours each of 
i^ c h  consists o f 4 observati<ms per group and are presorted as the mean ± SBVL
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Figure 8: EOects o f f^nmatnswin-14 and IL-16 on IL-6 release from C6 glioma cells.
C6 cells (100 X 10^  cells/well) were incubated in the presoice o f vehicle (SF-RPMI), IL- 
ip  (100 ng/ml) and IL-ip (100 ng/ml) + Somatostatin-14 (SRIF-14) (0 to 200 oM). The 
data are formed fum  treatment groups incubated for 24 hours each of which consists o f 4 
observations per group and are presented as Ae mean ± SEM.
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Figure 9: Effects o f Somalostatin-14 anrl iL -ip  on IL-6 release from C6 glioma cells. 
C6 cells (100 X 10^  cells/well) were incubated in the {xesence o f vdncle (SF-RPMI), 
Somatostatin-14 (SRIF-14) (200 nM), IL-ip (0 to 50 ng/ml) and IL-lp (0 to 50 ng/ml) + 
Somatostatin-14 (SRIF-14) (200 nM). The data are formed 6mn treatment groups 
incubated for 24 hours each o f which consists o f 4 observations per group and are 
presented as Ae mean ± SEM.
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Figure 10: EfGacts o f Somatostatm-14. IPT. PRO and IL-ip on lL-6 release 6om  C6 
glioma cells. C6 cells (100 x 10^  cells/well) were incubated in the {uesence o f vehicle 
(SF-RPMI), IL-lp (100 ng/ml), IL-lp (100 ng/ml) + IPT (10 uM), IL-lp (100 ng/ml) + 
IPT (10 uM) + PRO (10 uM), IL-lp (100 ng/ml) + SRIF-14 (200 nM) and IL-lp (100 
ng/ml) + IPT (10 uM) + SRIF-14 (2000 nM). The data are Rmned 6om  treatment groups 
incubated 5>r 24 hours each o f which consists o f 4 observations p a  group and are 
piesaited as the mean ± SEM.
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Figure 11: Efkcts o f Somalostatin-28 and IL-16 on IL-6 release 6om C6 dioma cells. 
C6 cells (100 X 10^  cells/well) were iwubated in die presence o f vehicle (SF-RPMI), IL- 
1 p (50 n^ml) and IL-1 p (50 ng/ml) + Somatostatin-28 (SRIF-28) (0 to 200 nM). The 
data are dinned &om treatment groups inculKrted fbr 24 hours each o f which consists o f 4 
observations per group and are presented as die mean± SEM.
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Figure 12: Effects o f Somatostatin-28 and IL-ip on IL-6 release from C6 elioma ceUs. 
C6 cells (100 X 10^  cells/well) were incubated in the presence o f vehicle (SF-RPMI), 
Somatostatin-28 (SRIF-28) (200 nM), IL-lp (0 to 50 ng/ml) and IL-lp (0 to 50 ng/ml) + 
SRIF-28 (200 nM). TlK data are formed dom treatment groups incubated fbr 24 hours 
eadi o f which consists o f 4 observations per group and are (xesented as the mean ± SEM.
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Figure 13: ElQkcts o f SomatostatmrZS. IPT. PRO and IL-16 on IL-6 rdaise Grom C6 
elioma cells. C6 cells (100 x 10' cells/well) were incubated in the presence o f vehicle 
(SF-RPMI), IL-lp (50 ng/ml), IL-ip (50 ng/ml) + IPT (10 uM), IL-ip (50 ng/ml) + IPT 
(10 uM) + PRO (10 uM), IL-lp (50 ng/ml) + SRIF-28 (200 nM) and IL-lp (50 ng/ml) + 
IPT (10 uM) + SRIF-28 (200 nM). The data are formed 6om  treatment groups incubated 
fbr 24 hours each o f which consists o f 4 observations per group and are presented as the 
mean ± SEM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
38
250
200
150
i
d 100
50
0
O Control 
BIL-IB (50 ng/ml) 
mSRIF-14 (nM) + IL-IB (50 ng/ml) 
mSRIF-28 (uM) + IL-IB (50 ng/ml)
i
i  ;
0 25 50
SRIf (nM)
100 200
Figure 14: Eflècts o f Somatostatin-14 Somatostadn-28 and IL-lp on IL-6 release 6om  
C6 elioma cells C6 ceUs (100 x 10^  cells/well) were incubated in the presence o f vehicle 
(SF-RPMI), IL-ip (50 ng/ml). Somatostatin-14 (SRIF-14) (0 to 200 nM) + IL-ip (50 
ng/ml) and Somatostatin-28 (SRIF-28) (0 to 200 nM) + IL-ip (50 ng/ml). The data are 
formed horn treatment groups incubated fbr 24 hours each o f whidi consists of 4 
observations per grorq* and are presented as the mean ± SEM.
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Figure 15: EfÏMts o f Y-amino-n-butvric acid (GABA) and IL-6 on 71D1 cell bioassav 
standard curve. 7TD1 cells (8,000 cells/well) were incubated in the presence o f IX- 
7TD1 media, IL-6 (0.5 to 64 pg/well) and IL-6 (0.5 to 64 pg/well) + GABA (50 pM).
The data are formed &om treatmœt groiq» incubated Ar 24 hours each of which (xmsists 
o f 4 observations per group and are pnesaited as the mean ± SEM.
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Figure 16: EGects o f IL-lp and v-amino-n-butvric ^ id  fGABAl on IL-6 release ûom C6 
^ om a cells. C6 cells (100 x 10^  cells/well) were incubated in the presence o f vehicle 
(SF-RPMI) = 555.24 +/_ 50.89, IL-lp (50 ng/ml) = 1898.999 +/_ 132.08, IL-lp (50 
ng/ml) + Y'^ innno-n-butyric acid (GABA) (0 -1000 pM) and y-amino-n-bulyTic acid 
(GABA) (1000 pM) = 127.72 +/- 34.47. The data are formed from treatment groups 
iiK;ulmtedfbr24 hours eadi o f vduch consists o f4 obsavatxms pergnmqpandswe 
prewaüedastheineanaSEQWL
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Figpjre 11^  Efkcts of IL-ip and v-ammo-n-butvric add IGABAl on IL-6 release from C6 
elioma cells. ()6 cells (lOOiK IC^œUs/well) wnere ûacidbate(lintbK:{%n3BeiK)e<)f)yeliH:k; 
(SF-RPMI), IL-ip (0 to 25 ng/ml) and IL-ljp (0 to 25 ngW ) + y-aniino-n-bu^c acid 
(G/VB/l) (1CW)0 pM). THbcidata are formed frcHniMxdünerü gpoiqps ûic%d]0le%iix)ri24 liomuns 
eadiofvdnchconsü^of4<dMerMdimispergnmq)aDdarepmBM%üedastbenM%m±5H3VL
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Figure 18: Efkcts o f y-aminn-n-butyric acid (GABA l IPT. PRO and IL-ip on IL-6 
release &om C6 ^ioma celk. C6 cells (100 x 10^  cells/well) w ae incubated in the 
presmce o f vehicle (SF-RPMI), IL-ip (50 ng/ml), IL-ip (50 ng/ml) + IPT (10 uM), IL- 
ip  (50 ng/ml) + IPT (10 uM) + PRO (10 uM), IL-lp (50 ng/ml) + GABA (1000 nM) and 
IL-lp (50 ng/ml) + IPT (10 uM) + GABA (KXX) nM). The data are formed ûom  
treatment groiqis incubated for 24 hours eadi o f Wiich consists o f 4 observations pa" 
groiq) and are presented as t k  mean ± SEM.
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Figure 19: Efkcts o f varvine types of LvsophosphatidvlcholiDe ILPC 10 to 201 and IL- 
ip  on IL-6 release &om C6 glioma cells C6 cells (100 x 10^  cellsAveU) were incubated 
in 6 e  presmce o f vehicle (SF-RPMI); IL-16 = 105.51 +/- 14.19, varying types o f LPC 
(10 to 20) (0.625 to 40 pM) and IL-lp (50 ng/ml); IL-6 = 1228.45 +/- 35.41. The data 
are formed &om treatmait groups incubated for 24 hours each o f Wiich consists o f 4 
observations per group and are presented as die mean ± SEM.
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Figure 20: Effects o f IL-ip. IsoprotaunoL PrO(xanolol and LPC-18 on IL-6 release &om 
C6 elioma cells. C6 cells (100 x 10^  cells/well) were iwubated in the inesence o f vehicle 
(SF-RPMI), IPT (10 uM), PRO (10 uM), IL-ip (50 ng/ml), IL-lp (50 ng/ml) + IPT (10 
uM), IL-ip (50 ng/ml) + IPT (10 uM) + PRO (10 uM), LPC-18 (0 to 40 uM), LPC-18 (0 
to40uM ) + IPT(10uM )andLPC-18(0to40uM ) + IPT (10uf^  + PRO(10uM). The 
data are fmmed Aom treatment groups incubated Ar 24 hours each o f which cmisists o f 4 
(Aservahons per group and are presented as the mean ± SEM.
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Figure 21: EAects o f LPC-18. IPT. PRO and SRIF-14 on IL-6 release Aom C6 elioma 
cells. C6 cells (100 x 10^  ceUs/well) were incubated in the preseice o f vehicle (SF- 
RPMI), LPC-18 (20 uM), L P 018 (20 uM) + IPT (10 uM), LPC-18 (20 uM) + IPT (10 
uM) + PRO (10 uM), LPC-18 (20 uM) + SRIF-14 (200 nM) and L P 018 (20 uM) + IPT 
(10 uM) + SRIF-14 (200 nM). The data are Armed Aom treatment groups incubated Ar 
24 hours each o f which consists o f 4 observations per groiq) and are ;aesented as the 
mean ± SEM.
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Figure 22: EF&cts o f SB203580 and IL-6 on 711)1 cell bioassav standard curve. 7TD1 
cells (8,000 cells/weU) were incubated in the [x^esaice o f 1X-7TD1 media, IL-6 (0.25 to 
32 pg/well) aiwl IL-6 (0.25 to 32 pg/well) + SB203580 (.5 uM/well). The data are 
farmed 6om treatment groups incubakd for 24 hours each o f which consists o f 4 
observations per group and are presmted as the mean ± SEM.
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Figure 23: Effects o f SB203580. IL-16 and LPC-18 on IL-6 release from C6 elioma 
cells. C6 cells (1(X) x 10^  cells/well) were incubated in the piesetKe o f vehicle (SF- 
RPMI), IL-lp (50 ng/ml), LPC-18 (40 uM), LPC-18 (40 uM) + SB203580 (0 tolO uM) 
and IL-lp (50 ng/ml) + SB203580 (0 to 10 uM). The data are formed from treatment 
groups incubated for 24 hours each o f which consists o f 4 observations per grotq) and are 
presented as the mean ± SEM.
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Figure 24: Efkcts o f SB203580 and IL-ip on IL-6 release from C6 elioma cells. C6 
cells (100 X 10^  cells/well) were incubated in the presence o f vehicle (SF-RPMI), IL-ip 
(0 to 50 ng/ml) and SB203580 (10 uM) + IL-ip (0 to 50 ng/ml). The data are formed 
from treatment grotqxs eadi o f vthich consists o f 4 observations pa: group and are 
presented as the mean ± SEM.
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Figure 25: EfRxAs o f SB203580. SP600125 and IL-16 on IL-6 release &om C6 elioma 
cells. C6 cells (100 x 10^  ceUs/well) were incubated in the presence o f vehicle (SF- 
RPMI), IL-lp (0 to 50 ng/ml), SB203580 (10 uM) + IL-lp (0 to 50 ng/ml) and SP600125 
(10 uM) + IL-ip (0 to 50 ng/ml). The data are formed from treatment groups incubated 
for 24 hours each o f which consists o f 4 observations per group and are presented as the 
mean ± SEM.
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Figure 26: ESects of SB203580. IL-IB and LPC-18 on IL-6 release from C6 glioma 
cells. C6 cells (100 x 10^  cells/well) were iixiubated in the pxesence o f vehicle (SF- 
RPMI), IL-lp (50 ng/ml), LPC-18 (0 to 40 uM) and LPC-18 (0 to 40 uM) + SB203580 
(10 uM). The data are formed from tr^tment groups incubated for 24 hours each of 
which crmsists o f 4 observations per groiq) and are presorted as the mean ± SEM.
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Figure 27: Efkcts o f SB203580. SP600125. E,-16 and LPC-18 on IL-6 release from C6 
elioma cells. C6 ceUs (100 x 10^  cells/well) were incubated in the presence o f vehicle 
(SF-RPMI), SB203580 (10 uM), SP600125 (10 uM), IL-ip (50 ng/ml), LPC-18 (0 to 40 
uM), LPC-18 (0 to 40 uM) + SB203580 (10 uM) and LPC-18 (0 to 40 uM) + SP600125 
(10 uM). The data are formed 6om  treatment groups incubated for 24 boms each o f 
which consists o f 4 obsmvations per group and are presarted as the mean ± SEM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
j"—  PRO
L?Ci&:0
\
m
cJm^NPKB,ATK 
I MAPK/MPK
? X
Î
Figure 28: Possible sipnalinp pathways resulting in IL-6 release and inhibition from C6 
elioma cells. AA, aracbidonic acid; AdCyc, adenylyl cyclase; ATF2, transcription &ctor 
ATF2; p^AdR, p-adrenergic receptm  ^cJun NH2-terminal kinase; GABA, y-aminobutyric 
acid; IL-ip, interleukin-1 P; IL-6, interleukin-6, IPT, Isofnoterenol (imireases cAMP 
levels); LPC, lysophosphatidylcholine; MAPK, mitogwactivated protein kinases; NE, 
norepinefArine; NFKB, nuclear factm xB; PC, phosfAatic^^lcholioe; PKC, protein kinase 
C; PLA2, phos;Aolipase A2; PRO, propranolol; SAPK, stress-activaW protein kinase; 
SRIF, somatostadn (reduces cAMP levels).
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